Bebtelovimab joins the long list of “here and gone” anti- SARS-CoV-2 monoclonal antibodies that are no longer reliably effective in treating COVID-19 due to mutations in the dominant variants of concern. For the past monoclonals such as REGEN-COV or sortovimab, Omicron rendered them ineffective.
Ask the Doctor Question: CLL patients tend to have reactions to monoclonal antibodies (my experience is with Rituxan) typically during their first infusion. With the development of the monoclonal antibody infusions for COVID, and the ones involved in the PROVENT
Ask the Lab Scientist Question: Has anyone tested to see of CLL patients who catch COVID before being vaccinated and get antibodies treatment, who then get vaccinated, should be given antibodies treatment regularly along with boosters? Would that keep their antibodies
Question: My question relates to certain reactions/side-effects to the Booster shot received 8/21/2021, not experienced previously with Pfizer doses 1 and 2 received in January/February 2021: Extreme fatigue, lack of energy, appetite, feeling out of sorts was anticipated. Not anticipated
Ask the Doctor Question: I have been Watch and Wait for four years, and have had two Pfizer vaccines, plus the booster. My immunoglobulin levels are low, but I have been able to keep healthy with masking, distancing, etc. My
Ask the Doctor Question: I had four successive adverse “anaphylactoid” reactions to rituximab, (as part of a Fludarabine-Rituximab protocol here in Vancouver, Canada) before that treatment was abandoned. Am I at greater than usual risk of anaphylactoid reaction to the
Ask the Doctor Question: Does taking ibrutinib inhibit, neutralize, or degrade the ability of antibodies (being) produced by REGEN-COV? Answer: No, it does not. This is because the antibodies found in the REGEN-COV infusion are already made and being directly injected
Ask the Doctor Question: During CLL Society’s COVID Virtual Community meeting on 9/24, did I understand Dr. Lamanna to say she is routinely giving her CLL patients prophylactic pre-exposure monoclonal antibody infusions? If so, can I get this from my oncologist?
Ask the Doctor Question: Since there now are a few treatments under way for the pre-exposure prophylaxis treatment for high-risk patients, such as AZD7442, Regeneron and the upcoming Molnupirar, is there some data (even if limited) regarding the medical advice
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
